Rigel Pharmaceuticals Inc (Rigel) is a biotechnology company which focuses on developing, discovering and advancing novel small-molecule drugs for the treatment of cancer, immune and hematologic disorders, and rare diseases. The company’s lead product, Tavalisse (fostamatinib disodium hexahydrate) an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of chronic immune thrombocytopenia (ITP) in adults.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Rigel’s R&D efforts focus on developing a portfolio of product through its own proprietary programs and by potential collaborative partners. In FY2022, the company spent US$60.3 million. Research and development accounted for 50.1% of the company's revenue in FY2022. As of December 31, 2022, Rigel had 376 issued and active patents in the US and 48 pending patent applications and corresponding pending foreign patent applications and issued foreign patents.